AstraZeneca Pushes Into GI Cancers With HIMALAYA And TOPAZ-1
Not Quite At The Summit But Tremelimumab Hits A High
Pivotal data presented at the ASCO GI meeting in liver and biliary tract cancers could add a couple of billion dollars to Imfinzi’s sales and breathe new life into the CTL4 inhibitor tremelimumab.
